Semaglutide is a Glucagon Like Peptide GLP agonist, Semaglutide has been shown to be effective in inducing weight loss in patients with obesity. Studies have shown that the infusion of GLP 1 results in reduced gastrointestinal emptying and an increased rate of fasting and postprandial gastric volumes, resulting in a decrease in hepatic glycemia. Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder among women of reproductive age, Semaglutide affects the brain’s hunger control centers, causing a reduction in food intake and an increased feeling of fullness, that is helpful in people who are struggling to lose weight. Multiple trials have shown that introduction of Semaglutide in regime helps with weight loss in patients of PCOD and is also effective in management of insulin resistance and lowering high levels of VLDL, LDL and triglycerides. Possible introduction of Semaglutide in the treatment of PCOD and obesity should be considered.